VIKING GLOBAL INVESTORS LP → BridgeBio Pharma, Inc. BBIO

Stake: 11.70% Shares: 22,055,375 CUSIP: 10806X102 Class: Common Stock, par value $0.001 per share

Item 4 — Purpose of Transaction

Item 4 of the Schedule 13D is hereby amended and supplemented as follows: On January 31, 2025, VGEM, VLFM and Opportunities Fund sold 143,266 shares of Common Stock, 57,020 shares of Common Stock and 2,865,330 shares of Common Stock, respectively, at a price of $34.90 per share.

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

4 13D/G filings on this issuer

3 other filings besides this one

Filer Track Record

5 filings by this filer

4 other filings in the data moat

Short Interest · settle 2026-03-31

DTC 14.73

23,366,752 shares short · -0.6% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $581K

Point72 Asset Mgmt

Post-Filing Returns · since 2025-01-31 on BBIO

+1 day

-9.3%

+5 days

-2.0%

+30 days

-3.5%

+60 days

-3.5%

+90 days

+12.2%

+180 days

+33.4%

Anchor price 34.21 on closest trading day on/after 2025-01-31. Source: Yahoo Finance daily adj_close (split + dividend adjusted).

Other 13D/G Filings on BridgeBio Pharma, Inc.

Filed	Form	Filer	Stake	Shares
2026-04-02	SCHEDULE 13D/A	VIKING GLOBAL INVESTORS LP	6.10%	11,842,434	view →
2025-07-01	SCHEDULE	VIKING GLOBAL INVESTORS LP	9.80%	18,602,920	view →
2025-03-07	SCHEDULE	KKR Genetic Disorder L.P.	10.10%	19,260,971	view →

Other Filings by VIKING GLOBAL INVESTORS LP

Filed	Form	Issuer	Stake	Shares
2026-04-02	SCHEDULE 13D/A	BridgeBio Pharma, Inc. BBIO	6.10%	11,842,434	view →
2025-07-01	SCHEDULE	BridgeBio Pharma, Inc. BBIO	9.80%	18,602,920	view →
2021-10-01	SC	Ginkgo Bioworks Holdings, Inc. DNABW	—	—	view →
2018-01-16	SC	Arbutus Biopharma Corp ABUS	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. $1,500/mo. Pilots welcome.

Request a pilot →